C. Flexner

发表

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

J. Lisziewicz, E. Rosenberg, R. Siliciano, 1999, Nature Medicine.

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

M. Hughes, M. Hirsch, D. Kuritzkes, 2007, The Journal of infectious diseases.

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.

Tara L. Kieffer, R. Siliciano, J. Gallant, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Erratum: Marked intraindividual variability in antiretrovrial concentrations may limit the utility of therapeutic drug monitoring (Clinical Infectious Diseases (April 15, 2006) 42 (1189-1196))

Tara L. Kieffer, R. Siliciano, J. Gallant, 2006 .

Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo

James Theiler, Eoin Coakley, Bette Korber, 2009, PloS one.

HIV drug development: the next 25 years

Charles Flexner, C. Flexner, 2007, Nature Reviews Drug Discovery.

Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings

C. Flexner, G. Maartens, M. Boffito, 2017, Current opinion in HIV and AIDS.

Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling

C. Flexner, A. Owen, M. Siccardi, 2020, Antimicrobial Agents and Chemotherapy.

Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

C. Flexner, A. Owen, D. Back, 2019, The Journal of infectious diseases.

Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes.

C. Flexner, G. Lucas, R. Moore, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Harnessing nanostructured systems for improved treatment and prevention of HIV disease

C. Flexner, H. Cui, Maya K. Monroe, 2018, Bioengineering & translational medicine.

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Andrew Owen, Zoltan Szekely, C. Flexner, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir

C. Flexner, B. Caballero, A. Dobs, 2008, BMC complementary and alternative medicine.

Safety , Tolerability , and Pharmacokinetic Interactions of the Antituberculous Agent TMC 207 ( Bedaquiline ) With Efavirenz in Healthy Volunteers : AIDS Clinical Trials Group Study A 5267

K. Dooley, J. Park, C. Flexner, 2012 .

HIV INFECTIONS AND AIDS

Charles Williams Flexner, C. Flexner, Paul A. Pham, 2009 .

Direct-acting antiviral agents for hepatitis C virus infection.

C. Flexner, J. Kiser, 2013, Annual review of pharmacology and toxicology.

Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression

B. Moss, C. Flexner, A. Hügin, 1987, Nature.

Dextran sulfate is poorly absorbed after oral administration.

C. Flexner, C. Hendrix, P. Lietman, 1989, Annals of internal medicine.

Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection

R. Chaisson, C. Flexner, H. Farzadegan, 1991, Antimicrobial Agents and Chemotherapy.

LONG-ACTING DRUGS AND FORMULATIONS FOR THE TREATMENT AND PREVENTION OF HIV.

C. Flexner, S. Swindells, A. Owen, 2020, International journal of antimicrobial agents.

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects

K. Dooley, C. Flexner, S. Piscitelli, 2013, Journal of acquired immune deficiency syndromes.

Pharmacokinetic Modeling of Plasma and Intracellular Concentrations of Raltegravir in Healthy Volunteers

C. Flexner, B. Goh, E. Yong, 2011, Antimicrobial Agents and Chemotherapy.

Possible Differential Induction of Phase 2 Enzyme and Antioxidant Pathways by American Ginseng, Panax quinquefolius

C. Flexner, T. Parsons, P. Lietman, 2008, Journal of clinical pharmacology.

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

M. Hughes, D. Kuritzkes, C. Flexner, 2009, The Journal of infectious diseases.

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers

J. Park, C. Flexner, C. Hendrix, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic/Pharmacodynamic Modeling of the Antiretroviral Activity of the CCR5 Antagonist Vicriviroc in Treatment Experienced HIV-Infected Subjects (ACTG Protocol 5211)

M. Hughes, D. Kuritzkes, C. Flexner, 2010, Journal of acquired immune deficiency syndromes.

Long-Acting HIV Drugs for Treatment and Prevention.

C. Flexner, R. Gulick, 2019, Annual review of medicine.

The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive

C. Flexner, E. Ette, P. Barditch-Crovo, 1999, Clinical pharmacology and therapeutics.

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.

Paige L. Williams, R. Chaisson, C. Flexner, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations

K. Dooley, J. Hackman, R. Chaisson, 2008, Antimicrobial Agents and Chemotherapy.

Ageing in patients with chronic HIV infection: impact of hypercoagulation

C. Flexner, S. Kent, 2018, AIDS Research and Therapy.

The Changing Face of HIV

C. Flexner, S. Willard, 2008 .

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Francoise F Giguel, M. Hughes, D. Kuritzkes, 2008, Journal of Virology.

Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection.

C. Flexner, Xiao-Fang Yu, J. Hildreth, 2002, The Journal of infectious diseases.

Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.

Caleb F. Anderson, C. Flexner, H. Cui, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Non-Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine.

R. Chaisson, D. Richman, C. Flexner, 1991, JAMA.

Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis

C. Flexner, S. Swindells, David L. Thomas, 2019, Current opinion in HIV and AIDS.

Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses.

P. Earl, B. Moss, S. Chakrabarti, 1988, Virology.

Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

C. Flexner, D. Ripin, K. Crawford, 2012, The Lancet. Infectious diseases.

The critical need for alternative antiretroviral formulations, and obstacles to their development.

C. Flexner, S. Swindells, C. Fletcher, 2011, The Journal of infectious diseases.

Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1–Infected Treatment-Experienced Patients

M. Hughes, M. Hirsch, D. Kuritzkes, 2010, Journal of acquired immune deficiency syndromes.

HIV genotype and phenotype--arresting resistance?

C. Flexner, 2000, JAMA.

Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects.

C. Flexner, A. Andrade, Lawrence S Lee, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe neutropenia among healthy volunteers given rifabutin in clinical trials

C. Flexner, P. Barditch-Crovo, P. Barditch‐Crovo, 2003 .

Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART

Tara L. Kieffer, R. Siliciano, A. Wu, 2005, HIV clinical trials.

Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations

C. Flexner, S. Rannard, A. Owen, 2019, Nanoscale advances.

Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies

C. Flexner, D. Meyers, S. Rannard, 2019, Nature Communications.

Amprenavir and Lopinavir Pharmacokinetics following Coadministration of Amprenavir or Fosamprenavir with Lopinavir/Ritonavir, with or without Efavirenz

C. Flexner, P. Barditch-Crovo, K. Carson, 2007, Antiviral therapy.

High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

M. Lederman, C. Flexner, B. Dezube, 1995, The Journal of infectious diseases.

Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.

B. Moss, B. Murphy, C. Flexner, 1990, Vaccine.

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis

C. Flexner, A. Phillips, P. Revill, 2021, The Lancet. Global health.

Repeated hospitalization for diabetic ketoacidosis. The game of "Sartoris".

C. Flexner, P. Dans, J. Weiner, 1984, The American journal of medicine.

Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?

C. Flexner, Matthew M. Ippolito, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?

C. Flexner, Matthew M. Ippolito, 2020 .

Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects

J. Weinstein, C. Flexner, C. Hendrix, 1994, Antimicrobial Agents and Chemotherapy.

The antiretroviral drug pipeline: prospects and implications for future treatment research

C. Flexner, M. Saag, 2013, Current opinion in HIV and AIDS.

Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling.

C. Flexner, L. Rameh, Lianwei Jiang, 2004, American journal of physiology. Cell physiology.

Vaccinia Virus Expression Vectors a

B. Moss, C. Flexner, 1989, Annals of the New York Academy of Sciences.

Roles of vaccinia virus in the development of new vaccines.

B. Moss, C. Flexner, T. Fuerst, 1988, Vaccine.

Supramolecular nanomedicines through rational design of self-assembling prodrugs.

C. Flexner, H. Cui, Han Wang, 2022, Trends in pharmacological sciences.

Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method.

C. Flexner, B. Goh, L. Kong, 2011, Journal of mass spectrometry : JMS.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.

J. Meza, H. Sayles, H. Gendelman, 2013, Nanomedicine.

Drug development strategies for salvage therapy: conflicts and solutions.

M. J. van der Laan, D. Kuritzkes, J. Schapiro, 2006, AIDS research and human retroviruses.

Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers

C. Flexner, E. Yong, L. Lee, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when Co

C. Flexner, E. Yong, G. Soon, 2010 .

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.

M. Hughes, K. Tashima, R. Paredes, 2009, Clinical Infectious Diseases.

Rhesus monkey macrophages infected with simian immunodeficiency virus cause rapid lysis of CD4-bearing lymphocytes.

J. Clements, C. Flexner, M. Zink, 1991, The Journal of general virology.

Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.

D. Hazuda, C. Flexner, S. Swindells, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV.

M. Lederman, C. Flexner, C. del Rio, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

D. Kuritzkes, C. Flexner, C. Marzolini, 2022, Clinical pharmacology and therapeutics.

Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1.

C. Flexner, D. Norse, U. Sharma, 1996, Blood.

Current Status and Future Prospects of Therapeutic Drug Monitoring and Applied Clinical Pharmacology in Antiretroviral Therapy

M. Kurowski, C. Flexner, E. Acosta, 2005, Antiviral therapy.

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1.

M. Lederman, D. Clifford, D. Douek, 2016, AIDS research and human retroviruses.

Sporadic Urban Leptospirosis

C. Flexner, D. Kaslow, J. Vinetz, 1996, Annals of Internal Medicine.

Active Learning Centre: potential uses and efficacy of an interactive Internet-based teaching tool

H. Lehmann, C. Flexner, J. Shatzer, 2000 .

Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities

C. Flexner, S. Lockman, K. Mayer, 2019, The lancet. HIV.

The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

N. Ford, C. Flexner, A. Hill, 2018, AIDS.

Effect of indomethacin and aspirin on gastric blood flow and acid secretion.

C. Flexner, J. Oates, D. Shand, 1977, The Journal of pharmacology and experimental therapeutics.

Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.

C. Flexner, R. Bosch, I. Frank, 2007, AIDS research and human retroviruses.

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

C. Flexner, G. Maartens, M. Marzinke, 2019, The Journal of antimicrobial chemotherapy.

Protease Inhibitors in AIDS Therapy

C. Flexner, R. Ogden, 2001 .

Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.

C Flexner, Stephen D. Sisson, S. Goodman, 1996, The American journal of medicine.

HIV-protease inhibitors.

C. Flexner, 1998, The New England journal of medicine.

Combination antiretroviral therapy for HIV infection.

C. Flexner, J. Maenza, 1998, American family physician.

The effect of systemically administered recombinant human nerve growth factor in healthy human subjects

C. Flexner, D. Cornblath, S. Peroutka, 1994, Annals of neurology.

Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.

C. Flexner, T. Blaschke, L. Sheiner, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Drug interactions in patients infected with human immunodeficiency virus.

M. Polis, H. Masur, C. Flexner, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries.

K. Dooley, C. Flexner, A. Andrade, 2008, The Journal of infectious diseases.

Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection

Dominique Schols, M. Lederman, C. Flexner, 2004, Journal of acquired immune deficiency syndromes.

Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers

Edward J. Fuchs, Craig W. Hendrix, Charles Flexner, 2000, Antimicrobial Agents and Chemotherapy.

Emerging antiretroviral drug interactions.

C. Flexner, P. Pham, 2011, The Journal of antimicrobial chemotherapy.

Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine

M. Lederman, T. Shapiro, C. Flexner, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Universal antiretroviral regimens: thinking beyond one-pill-once-a-day

C. Flexner, J. Jacobson, 2017, Current opinion in HIV and AIDS.

Vaccinia virus expression vectors.

B. Moss, C. Flexner, 1987, Annual review of immunology.

Long-acting implants to treat and prevent HIV infection.

C. Flexner, E. Weld, 2019, Current opinion in HIV and AIDS.

Antiretroviral implants for treatment and prevention of HIV infection

C. Flexner, 2018, Current opinion in HIV and AIDS.

Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.

C. Flexner, R. Bosch, I. Frank, 2004, AIDS research and human retroviruses.

Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?

Richard D Moore, C. Flexner, G. Lucas, 2002, AIDS patient care and STDs.

Principles of clinical pharmacology in postexposure prophylaxis.

C. Flexner, 1997, The American journal of medicine.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Tara L. Kieffer, Joel E Gallant, Charles Flexner, 2005, JAMA.

Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.

C. Flexner, R. Bollinger, C. Thio, 2019, The lancet. HIV.

Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies

C. Flexner, D. Meyers, S. Rannard, 2019, Nature Communications.

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV

Marco Siccardi, Andrew Owen, Steve Rannard, 2015, Clinical Pharmacokinetics.

The future of long-acting agents for preexposure prophylaxis

C. Flexner, 2022, Current opinion in HIV and AIDS.

Biphasic Elimination of Tenofovir Diphosphate and Nonlinear Pharmacokinetics of Zidovudine Triphosphate in a Microdosing Study

Steven R Tannenbaum, Charles Flexner, C. Flexner, 2012, Journal of acquired immune deficiency syndromes.

Modern Human Immunodeficiency Virus Therapy: Progress and Prospects

C. Flexner, 2018, Clinical pharmacology and therapeutics.

Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.

C. Flexner, A. Owen, Eneko Larrañeta, 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

CHEMOTHERAPY FOR HIV-ASSOCIATED NON-HODGKIN LYMPHOMA (HIV-NHL) IN COMBINATION WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS NOT ASSOCIATED WITH EXCESSIVE TOXICITY.

L. Grochow, C. Flexner, D. Scadden, 1999 .

Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.

C Flexner, C. Flexner, M. Jacobson, 1994, The Journal of infectious diseases.

Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.

J. Schapiro, C. Flexner, T. Blaschke, 2006 .

Simplification of Antiretroviral Therapy: A Necessary Step in the Public Health Response to HIV/AIDS in Resource-Limited Settings

N. Ford, C. Flexner, M. Vitoria, 2014, Antiviral therapy.

Simplifying antiretroviral therapy.

C. Flexner, J. Eron, M. Tapper, 2004, The AIDS reader.

M. Lederman, C. Flexner, R. Pollard, 2010, AIDS research and human retroviruses.

The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors: Implications for Once-Daily Dosing

C. Flexner, D. Back, J. Gerber, 2005, Journal of acquired immune deficiency syndromes.

Alcohol use and HIV pharmacotherapy.

C. Flexner, L. Cheever, V. Cargill, 2002, AIDS research and human retroviruses.

Slow efavirenz metabolism genotype is common in Botswana.

T. Tenhave, B. Strom, C. Flexner, 2008, Journal of acquired immune deficiency syndromes.

Beneficial Pharmacokinetic Interaction Between Atazanavir and Lopinavir/Ritonavir

C. Flexner, K. Carson, E. Fuchs, 2007, Journal of acquired immune deficiency syndromes.

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

C. Flexner, M. Karlsson, P. Olliaro, 2016, The Journal of antimicrobial chemotherapy.

Interest of Youth Living With HIV in Long-Acting Antiretrovirals

Md. Sohel Rana, C. Flexner, S. Swindells, 2019, Journal of acquired immune deficiency syndromes.

Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring.

C. Flexner, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study

M. Lederman, C. Flexner, C. del Rio, 2021, Journal of clinical pharmacology.

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.

L. Grochow, C. Flexner, D. Scadden, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimization and simplification of antiretroviral therapy for adults and children

N. Ford, C. Flexner, D. Ripin, 2013, Current opinion in HIV and AIDS.

OPINION Optimization and simplification of antiretroviral therapy for adults and children

N. Ford, C. Flexner, S. Vella, 2013 .

Therapeutic Drug Monitoring and Drug–Drug Interactions Involving Antiretroviral Drugs

David Back, David Burger, Charles Flexner, 2005, Antiviral therapy.

In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents

C. Flexner, S. Rannard, A. Owen, 2018, Clinical Pharmacokinetics.

Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers

C. Flexner, E. Yong, L. Lee, 2010, Antiviral therapy.

Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition

R. Siliciano, P. Earl, B. Moss, 1990, The Journal of experimental medicine.

An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes.

J. Berzofsky, B. Moss, R. Germain, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacoecology: A New Name for an Old Science

C. Flexner, Charles Flexner, 2008, Clinical pharmacology and therapeutics.

New approaches to vaccination.

C. Flexner, Charles Flexner, 1990, Advances in pharmacology.

Mutations of the Human Immunodeficiency Virus Type 1 p6Gag Domain Result in Reduced Retention of Pol Proteins during Virus Assembly

C. Flexner, C. Tian, L. Dawson, 1998, Journal of Virology.

macrophages. virus infection in with those of neutralizing antibodies on simian Comparison of the effects of 3'-azidothymidine

C. Flexner, H. Farzadegan, M. Mcentee, 2013 .

Comparison of the effects of 3'-azidothymidine with those of neutralizing antibodies on simian immunodeficiency virus infection in macrophages

C. Flexner, H. Farzadegan, M. Mcentee, 1993, Antimicrobial Agents and Chemotherapy.

Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.

Daniel I. S. Rosenbloom, R. Siliciano, J. Gallant, 2020, The lancet. HIV.

Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study

Daniel I. S. Rosenbloom, R. Siliciano, J. Gallant, 2020 .

HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals.

B. Walker, R. Schooley, M. Hirsch, 1988, Science.

Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen

B. Moss, B. Murphy, C. Flexner, 1988, Nature.

Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

R. Young, B. Walker, R. Schooley, 1989, Proceedings of the National Academy of Sciences of the United States of America.

The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.

C. Flexner, Jane Smith, 2017, AIDS.

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.

M. Lederman, D. Kuritzkes, C. Flexner, 2013, The Journal of infectious diseases.

HIV Cure: Knocking on the Door

C. Flexner, C. Durand, 2013, Clinical pharmacology and therapeutics.

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.

C. Flexner, 2000, Annual review of pharmacology and toxicology.

C. Flexner, A. Andrade, 2000, AIDS clinical care.

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.

Michael I. Jordan, S. Delany-Moretlwe, R. Paredes, 2023, The lancet. HIV.

Chemotherapy f or H uman I mmunodeficiency Virus-Associated N on-Hodgkin's L ymphoma i n Combination W ith H ighly A ctive A ntiretroviral T herapy

L. Grochow, C. Flexner, D. Scadden, 2001 .

Induction of chemoprotective phase 2 enzymes by ginseng and its components.

C. Flexner, Xiaoguang Lei, J. Fahey, 2009, Planta medica.

Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.

C. Flexner, S. Swindells, A. Owen, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

C. Flexner, M. Rudek, R. Ambinder, 2011, The Lancet. Oncology.

Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis.

R. Haubrich, G. Robbins, C. Flexner, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Eoin Coakley, Robert Gross, Wayne Greaves, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, Tolerability, and Antiretroviral Effects of Ritonavir‐Nelfinavir Combination Therapy Administered for 48 Weeks

J. Gallant, C. Flexner, S. Eshleman, 2000, Journal of acquired immune deficiency syndromes.

Complications of HIV therapy.

J. Bartlett, C. Flexner, 2000, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors*

C. Flexner, M. Lane, P. Kwiterovich, 2000, The Journal of Biological Chemistry.

Clearance of recombinant vaccinia virus expressing IL-2: role of local host immune responses.

B. Moss, C. Flexner, A. Hügin, 1993, Cellular immunology.

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions

D. Kuritzkes, C. Flexner, C. Marzolini, 2022, Annals of Internal Medicine.

Concentration-targeted therapy and the future of HIV management.

C. Flexner, S. Piscitelli, 2002, AIDS.

Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151.

R. Haubrich, D. Richman, C. Flexner, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Factors Associated With CD8+ T-Cell Activation in HIV-1–Infected Patients on Long-term Antiretroviral Therapy

C. Flexner, R. Bosch, A. Collier, 2014, Journal of acquired immune deficiency syndromes.

Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors

C. Flexner, C. Tian, Xiao-Fang Yu, 2000, Antimicrobial Agents and Chemotherapy.

(3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatment.

C. Flexner, Xiaoguang Lei, J. Fahey, 2008, Tetrahedron letters.

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID‐19 Therapeutic Development

P. Horby, C. Flexner, E. Acosta, 2020, Clinical pharmacology and therapeutics.

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.

R. Haubrich, C. Flexner, S. Piscitelli, 2001, Journal of acquired immune deficiency syndromes.

Forecast for the Physician Payment Sunshine Act: Partly to Mostly Cloudy?

Stephanie R. Morain, C. Flexner, N. Kass, 2014, Annals of Internal Medicine.

Post-exposure prophylaxis revisited: new CDC guidelines. Centers for Disease Control and Prevention.

C. Flexner, 1998, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions

M. Hughes, D. Kuritzkes, C. Flexner, 2009, Journal of Clinical Microbiology.

Prostaglandin and histamine involvement in the gastric vasodilator action of pentagastrin.

C. Flexner, J. Oates, D. Shand, 1977, The Journal of pharmacology and experimental therapeutics.

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeﬁciency Virus Type 1 Subtype C-Infected Subject (cid:1) †

D. Kuritzkes, C. Flexner, Z. Su, 2008 .

Steady‐state pharmacokinetic interaction of modified‐dose indinavir and rifabutin

C. Flexner, P. Deutsch, Hulin Wu, 2003, Clinical pharmacology and therapeutics.

Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.

C. Flexner, L. Lee, P. Pham, 2012, Annals of the Academy of Medicine, Singapore.

Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

C. Flexner, E. Fuchs, M. Elgadi, 2009, Antimicrobial Agents and Chemotherapy.

Payment to Healthy Volunteers in Clinical Research: The Research Subject's Perspective

C Flexner, C. Flexner, K. Carson, 2010, Clinical pharmacology and therapeutics.

Accelerator Mass Spectrometry Measurement of Intracellular Concentrations of Active Drug Metabolites in Human Target Cells In Vivo

C. Flexner, C. Fletcher, W. Hubbard, 2010, Clinical pharmacology and therapeutics.

Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects

J. Park, C. Flexner, C. Hendrix, 2007, Antimicrobial Agents and Chemotherapy.

Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401

C. Flexner, A. Hsu, J. Aberg, 2001, Journal of acquired immune deficiency syndromes.

Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.

C. Flexner, A. Hsu, J. Aberg, 2001 .

High-Dose Lopinavir/Ritonavir in Highly Treatment-Experienced HIV-1 Patients: Efficacy, Safety, and Predictors of Response

D. Podzamczer, C. Katlama, D. Havlir, 2007, HIV clinical trials.

Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors

C. Flexner, T. Blaschke, L. Sheiner, 2003, Clinical pharmacology and therapeutics.

Balancing Justice and Autonomy in Clinical Research With Healthy Volunteers

C Flexner, C. Flexner, K. Carson, 2007, Clinical pharmacology and therapeutics.

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR 4 Antagonist AMD 070 in Healthy Volunteers †

J. Park, C. Flexner, C. Hendrix, 2008 .

Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers (cid:1) †

J. Park, C. Flexner, C. Hendrix, 2008 .

Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy.

C. Flexner, V. Cargill, L. Cheever, 2001, AIDS patient care and STDs.

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

C. Flexner, R. Gross, T. Flanigan, 2009, Archives of internal medicine.

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

C. Flexner, R. Gross, J. Aberg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multi-scale system pharmacology modelling pipeline to assess the prophylactic efficacy of NRTIs against HIV-1 Mr

C. Flexner, M. Karlsson, P. Olliaro, 2016 .

The pharmacokinetic profiles of some dual protease inhibitor regimens support further investigation of once-daily dosing

C. Flexner, 2022 .

Advancing use of long‐acting and extended delivery HIV prevention and treatment regimens

S. Delany-Moretlwe, C. Flexner, José A. Bauermeister, 2023, Journal of the International AIDS Society.

Diagnosis of human immunodeficiency virus infection using citrated whole blood

C. Flexner, H. Farzadegan, U. Sharma, 1997, Clinical and diagnostic laboratory immunology.

Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers: AIDS Clinical Trials Group Study A5267

K. Dooley, J. Park, C. Flexner, 2012, Journal of acquired immune deficiency syndromes.

Why a universal antiretroviral regimen?

C. Flexner, P. Clayden, W. D. Venter, 2017, Current opinion in HIV and AIDS.

3-deaza-adenosine and inhibition of HIV

C. Flexner, R. Kuncl, D. Drachman, 1992, The Lancet.

Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?

C. Flexner, R. Bollinger, Linda L Lewis, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

What Clinicians Need to Know About the Development of Long-Acting Formulations.

C. Flexner, S. Swindells, David L. Thomas, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments.

C. Flexner, S. Swindells, G. Traverso, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of long-acting therapies on the global HIV epidemic.

C. Flexner, S. Rannard, A. Owen, 2021, AIDS.

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations

Lee M. Tatham, Christopher A. W. David, C. Flexner, 2023, Pharmaceutics.

Pharmacology of Antiretroviral Drugs

C. Flexner, C. Merry, 2008 .

Herbal Remedies in Resource‐poor Settings: Friend or Foe?

K. Dooley, C. Flexner, A. Andrade, 2008, Clinical pharmacology and therapeutics.

Treatment optimization: an outline for future success.

C. Flexner, Ben Plumley, David H Brown Ripin, 2013, Current opinion in HIV and AIDS.